Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Irritable Bowel Syndrome With Constipation · Chronic Constipation · IRWD

IRONWOOD PHARMACEUTICALS

IRONWOOD PHARMACEUTICALS INC

IRONWOOD PHARMACEUTICALS clinical programs — 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
100 Summer Street, Boston, MA 02110, US HQ
1998 Founded
262 Employees
Public company Type
IRWD · NYSE Ticker
Company details
Status
Public
HQ
100 Summer Street, Boston, MA 02110, US
Founded
1998
Employees
262
Programs
33
Drugs
11
Patents
45
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

IRONWOOD PHARMACEUTICALS projects

15 ClinicalTrials.gov programs sponsored by IRONWOOD PHARMACEUTICALS.

IRONWOOD PHARMACEUTICALS has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

15 programs

Clinical programs

  1. IW-3300 rectal foam

    IRONWOOD PHARMACEUTICALS INC

    Interstitial Cystitis

    phase 2 small molecule terminated

    1 trial

  2. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial

  3. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  4. IW-6118

    IRONWOOD PHARMACEUTICALS INC

    Healthy

    phase 2 small molecule completed

    1 trial

  5. IW-9179

    IRONWOOD PHARMACEUTICALS INC

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  6. IW-9179

    IRONWOOD PHARMACEUTICALS INC

    Dyspepsia

    phase 2 small molecule terminated

    1 trial

  7. Linaclotide 145 micrograms

    IRONWOOD PHARMACEUTICALS INC

    Opioid-Induced Constipation

    phase 2 small molecule completed

    1 trial

  8. Linaclotide Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule completed

    1 trial

  9. Linaclotide Dose A

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule terminated

    1 trial

  10. MD-0727

    IRONWOOD PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  11. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  12. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Constipation

    phase 2 small molecule completed

    1 trial

  13. MD-7246

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Diarrhea (IBS-D)

    phase 2 small molecule completed

    1 trial

  14. Placebo

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation in Children Ages 6-17 Years

    phase 2 small molecule completed

    1 trial

  15. linaclotide acetate

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does IRONWOOD PHARMACEUTICALS have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.